Oncology Brothers· @OncBrothers · X·· 1 天前评分70
正文 · 机器翻译
IO + EV 前线治疗现已成为 MIBC 的 SoC！！但 postOP 设置中需要多少 EV？热切期待第 2 天 #ESMO26 上更多的数据/讨论！VOLGA 成为新的 SoC!!??!!
#gusm @myESMO #BladderCancer
330 浏览 · 3 赞 · 4 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.orgESMO 2026 - presidential LBA | VOLGA Phase III – Perioperative Durvalumab + Enfortumab Vedotin (EV) in cisplatin-ineligible/refusing patients: 📊 EV + Durva vs Control • 2-year EFS: 64% vs 45% (HR 0.51; p<0.0001) • 2-year OS: 78% vs 69% (HR 0.58; p=0.0027) • pCR: 45% vs 10% Adding tremelimumab improved EFS (HR 0.61) but no significant OS benefit yet, with higher grade 3/4 toxicity (42% vs 30%). 🔥can this stop the need of post op EV ? Probably yes . New SOC 🙂👍 Looking forward the full datasets @OncBrothers @OncoAlert @myESMO #ESMO26 #VOLGA #BladderCancer在 X 查看被引用的帖子
来源：Oncology Brothers · x.com